The Pharmaceutical Benefits Advisory Committee will consider a range of potential new listings at its March 2023 meeting, including a fixed-dose immunotherapy combination for melanoma and a new cholesterol-lowering biologic.
PBAC to consider anticipated new therapies at its March meeting
November 24, 2022 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Weight loss medicines drive revenue sales growth for Sigma and Wesfarmers Health
August 28, 2026 - - BioPharma -
Patients Australia put healthcare’s quiet achievers in the spotlight
August 28, 2026 - - Latest News -
Cheaper medicines save Australians $1.4 billion as pharmacists urge freeze for all patients
August 28, 2026 - - Latest News -
Mayne Pharma bets on women’s health and direct distribution after a difficult year
August 28, 2026 - - Latest News -
Cathy Freeman to headline 2026 Patient’s Choice Awards
August 27, 2026 - - Latest News -
Australian company secures Mitsubishi partnership to bring BioPQQ to market
August 26, 2026 - - Latest News -
Noxopharm pushes Sofra platform towards cancer proof of concept
August 26, 2026 - - Australian Biotech
